An independent Data Monitoring Committee reviewed Bristol Myers Squibb’s CheckMate -548 Phase III trial of Opdivo (nivolumab) plus current standard of care in patients with newly diagnosed glioblastoma multiforme with 06-methylguanine-DNA methyltransferase promoter methylation following surgical resection of the tumor, and indicated the study would not meet the primary endpoint of overall survival.

Merck & Co. said a phase 3 trial of the cancer drug Keytruda in combination with chemotherapy showed an increase in the amount of time patients lived with small cell lung cancer (SCLC) without it getting worse, but did not extend overall survival.